Bone and renal health in infants with or without breastmilk exposure to tenofovir-based maternal antiretroviral treatment in the PROMISE randomized trial.

Tichaona Vhembo,Kristin Baltrusaitis,Camlin Tierney,Maxensia Owor,Sufia Dadabhai,Avy Violari,Gerhard Theron,Dhayendre Moodley,Cynthia Mukwasi-Kahari,Kathleen George,John Shepherd,George K Siberry,Renee Browning,Mary Glenn Fowler,Lynda Stranix-Chibanda

Journal of acquired immune deficiency syndromes (1999)（2023）

引用 0|浏览14

暂无评分

摘要

Week 26 mean LS-BMC was lower in infants in the mART group compared with the iNVP group. However, this difference (∼0.23g) was less than the one-half sd considered potentially clinically relevant. No infant renal safety concerns were observed.

查看译文

关键词

infant, bone mineral content, renal health, tenofovir disoproxil fumarate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要